ArticleInfection2022
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).
Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Early versus late tracheostomy in critically ill COVID-19 patients.The Cochrane database of systematic reviews · 2023Pooled it
- Article
- Outcomes, Sequelae, and Ventilatory Strategies in Long COVID Patients with Severe ARDS: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Frameworks to support evidence-informed decision-making in public health and infectious disease prevention and control: a scoping review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Persistent mortality in critical COVID-19 ICU cases from wild-type to delta variant: A descriptive cohort study.Scientific reports · 2025Observational
- A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany.Infectious diseases and therapy · 2025Article
- K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact.Infectious diseases and therapy · 2024Article
- Period of hospitalization and mortality in transferred versus non-transferred COVID-19 patients: results from Germany.Scientific reports · 2024Article
- An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications.Virulence · 2023Review
- Antibiotic prescribing guideline recommendations in COVID-19: a systematic survey.EClinicalMedicine · 2023Article
- High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study.BMC pulmonary medicine · 2023Observational
- Impact of COVID-19 on Sedation Requirements during Veno-Venous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome.Journal of clinical medicine · 2023Article
- Automated Monitoring of Adherence to Evidenced-Based Clinical Guideline Recommendations: Design and Implementation Study.Journal of medical Internet research · 2023Article
- COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis.GMS infectious diseases · 2023Article
- Plasma markers of COVID-19 severity: a pilot study.Respiratory research · 2022Article
- Severe COVID-19-associated myocarditis with cardiogenic shock - management with assist devices - a case report & review.BMC anesthesiology · 2022Review
- Beyond Guidelines and Reports on Bacterial Co-/Superinfections in the Context of COVID-19: Why Uniformity Matters.Antibiotics (Basel, Switzerland) · 2022Article
- Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.Cell reports. Medicine · 2022Article
- Article
- The Potential for Increasing Risk of Consent Refusal in COVID-19 Trials: Considering Underlying Reasons and Responses.Annals of the American Thoracic Society · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 19 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19.
methodsThe guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation.
resultsThe guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D
conclusionFor COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.